1. Home
  2. MNSB vs IPHA Comparison

MNSB vs IPHA Comparison

Compare MNSB & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStreet Bancshares Inc.

MNSB

MainStreet Bancshares Inc.

HOLD

Current Price

$25.02

Market Cap

164.1M

Sector

Finance

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$1.86

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNSB
IPHA
Founded
2003
1999
Country
United States
France
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
164.1M
165.3M
IPO Year
2017
2014

Fundamental Metrics

Financial Performance
Metric
MNSB
IPHA
Price
$25.02
$1.86
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
20.4K
35.5K
Earning Date
04-20-2026
03-26-2026
Dividend Yield
1.68%
N/A
EPS Growth
210.00
N/A
EPS
1.05
N/A
Revenue
$135,615,000.00
N/A
Revenue This Year
$1.50
$180.36
Revenue Next Year
$3.77
N/A
P/E Ratio
$23.50
N/A
Revenue Growth
N/A
N/A
52 Week Low
$17.86
$1.18
52 Week High
$25.87
$2.71

Technical Indicators

Market Signals
Indicator
MNSB
IPHA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
MNSB
IPHA

About MNSB MainStreet Bancshares Inc.

MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: